Immunodeficiency Clinical Trials

110 recruitingLast updated: July 17, 2026

There are 110 actively recruiting immunodeficiency clinical trials across 47 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Bethesda, Maryland, United States, Baltimore, Maryland, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Immunodeficiency Trials at a Glance

110 actively recruiting trials for immunodeficiency are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Not Applicable with 27 trials, with the heaviest enrollment activity in Bethesda, Baltimore, and San Francisco. Lead sponsors running immunodeficiency studies include National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and Merck Sharp & Dohme LLC.

Browse immunodeficiency trials by phase

Treatments under study

About Immunodeficiency Clinical Trials

Looking for clinical trials for Immunodeficiency? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunodeficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunodeficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 110 trials

Recruiting
Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting

Genetic Basis of Immunodeficiency

Severe Combined Immunodeficiency
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT00055172
Recruiting
Not Applicable

The Trans-Led Care Study

Substance AbuseSubstance AddictionSubstance Use Disorder (SUD)+2 more
Illinois Institute of Technology124 enrolled1 locationNCT06880705
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting

Natural History of Bronchiectasis

Cystic FibrosisBronchiectasisAutoimmune Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)900 enrolled1 locationNCT00943514
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled55 locationsNCT07266831
Recruiting
Phase 4

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

HIV (Human Immunodeficiency Virus)HIV-1-infectionHIV
CAN Community Health200 enrolled10 locationsNCT07476339
Recruiting

NIAID Centralized Sequencing Protocol

autoimmunityPrimary ImmunodeficiencyAtopy+1 more
National Institute of Allergy and Infectious Diseases (NIAID)20,000 enrolled2 locationsNCT03206099
Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled30 locationsNCT07071623
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled81 locationsNCT07044297
Recruiting
Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting

Genetic Analysis of Immune Disorders

ImmunodeficiencyGATA2DOK 8+2 more
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled1 locationNCT00001467
Recruiting

The Mechanistic Biology of Primary Immunodeficiency Disorders

Primary Immunodeficiency Disorders
National Institute of Allergy and Infectious Diseases (NIAID)2,500 enrolled2 locationsNCT03394053
Recruiting
Phase 1Phase 2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting

Nice Human Immunodeficiency Virus (HIV) Cohort

Human Immunodeficiency Virus
Centre Hospitalier Universitaire de Nice2,000 enrolled1 locationNCT03690063
Recruiting
Not Applicable

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical CancerHuman Papillomavirus (HPV) InfectionHuman Immunodeficiency Virus (HIV) Infection
University of California, Irvine348 enrolled3 locationsNCT07209917